Optimistic Buy Rating for enGene Holdings Amid LEGEND Study Progress and Regulatory Advancements

Wells Fargo analyst Yanan Zhu has maintained their bullish stance on ENGN stock, giving a Buy rating today.

Yanan Zhu has given his Buy rating due to a combination of factors including enGene Holdings’ progress in their LEGEND study and the potential for regulatory advancements. The company is on track to release additional data from the LEGEND study in the second half of 2025 and aims to file a Biologics License Application by mid-2026, which are significant milestones for the company.
Furthermore, enGene Holdings has expanded its clinical trial sites in Europe and Asia, indicating strong enrollment and an increased clinical footprint. The feedback from the European Medicines Agency suggests that the data provided could support a Conditional Marketing Authorization for detalimogene, assuming a favorable benefit-risk profile. These developments, along with a solid cash position expected to fund operations into 2027, contribute to the optimistic outlook and Buy rating.

In another report released today, Raymond James also maintained a Buy rating on the stock with a $23.00 price target.